MedPath

Non-invasive Intermittent Theta Burst Stimulation of the Dorsolateral Prefrontal Cortex in Functional Movement Disorders

Phase 2
Recruiting
Conditions
Functional Movement Disorder
Interventions
Device: MagStim
Other: Sham Comparator
Registration Number
NCT05155059
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Brief Summary

Background:

Functional movement disorders (FMD) involve involuntary movements that are not due to a recognized neurological or medical cause. FMD can cause major disability. Researchers want to learn more to create better treatments for FMD.

Objective:

To test whether non-invasive brain stimulation using transcranial magnetic stimulation (TMS) improves FMD symptoms.

Eligibility:

People between the ages of 18 and 80 who have been diagnosed with FMD by a neurologist.

Design:

Participants will be randomly assigned to one of two groups. One group is an active brain stimulation group and the other is a sham brain stimulation group.

Participants will have a baseline visit. This will include:

Neurological exam

Questionnaires

Urine test

Brain MRI: Participants will lie in a machine that takes pictures of the body. They will be asked to respond to images on a screen while in the scanner.

Within 2 weeks of the baseline visit, participants will begin 5 daily sessions of TMS. The active group will have stimulation delivered to the brain via a coil. In the sham group, a dummy coil will be used that will not deliver stimulation. A total of three 3-minute cycles will be done in one visit. There will be 20-minute breaks between the cycles.

Participants will have visits 1 month, 2 months, and 6 months after their last day of TMS. Their FMD symptoms will be evaluated. They will complete health questionnaires. These visits can be in person or virtual.

Detailed Description

Study Description:

The purpose of this protocol is to investigate efficacy of intermittent theta burst stimulation (iTBS) targeting the left dorsolateral prefrontal cortex (DLPFC) in patients with functional movement disorders (FMD). Participants will be randomly assigned to receive either active iTBS or sham stimulation of the left DLPFC for 5 consecutive daily sessions.

Objectives:

Primary Objective: To investigate efficacy of iTBS of the left DLPFC on motor symptoms in patients with FMD

Secondary Objectives: To investigate efficacy of iTBS of the left DLPFC on mood symptoms and its effect on fronto-amygdala circuit on functional neuroimaging

Endpoints:

Primary Endpoint: Relative change in Functional Movement Disorder Rating Scale (S-FMDRS) from the baseline to 1 month after iTBS vs sham: 100 \*( S-FMDRS at one-month - S-FMDRS at baseline)/ S-FMDRS at baseline

Secondary Endpoints:

* S-FMDRS immediately after, 2 months and 6 months after the treatment

* HADS at 1 month, 2 months and 6 months after the treatment

* DLPFC-amygdala functional connectivity

* Amygdala BOLD response to emotional stimuli

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
TreatmentMagStimActive TMS stimulation using an active TMS coil
ControlSham ComparatorSham TMS stimulation using a sham coil
Primary Outcome Measures
NameTimeMethod
S-FMDRS1 month after iTBS

Short version of Functional Movement Disorder Rating Scale

Secondary Outcome Measures
NameTimeMethod
S-FMDRS2 and 6 months after iTBS

Short version of Functional Movement Disorder Rating Scale

CGI1, 2 and 6 months after iTBS

Clinical Global impression - scale of 1-7 to measure clinical improvement from the intervention

SF-361, 2 and 6 months after iTBS

Health related quality of life

Trial Locations

Locations (1)

National Institutes of Health Clinical Center

🇺🇸

Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath